Loading
Rare cancers are collectively common but each is too rare for normal trials. Link every rare cancer patient worldwide into one network with registries and trial designs built for small numbers.
Rare cancers make up roughly a quarter of cancer diagnoses and have worse survival; each is too infrequent for conventional trials and expertise is scattered. Networks such as EURACAN and the International Rare Cancers Initiative show partial solutions. The proposal is a global federated rare cancer network: a single patient-facing registration and referral pathway, standardised molecular workup, a shared registry with outcomes, and pre-agreed trial frameworks (Bayesian borrowing across related histologies, n-of-1 crossover designs, external control arms from the registry) accepted by regulators for approval decisions.
Shares EORTC, Basket, umbrella, and platform trials, Mesothelioma, Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Basket, umbrella, and platform trials, Regulatory divergence between regions, Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Mesothelioma, Rare and paediatric cancers without markets, Neuroendocrine tumours.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Mesothelioma, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).